1 Simon JA, Anderson RA, Ballantyne E, Bolognese J, Caetano C, Joffe H, Kerr M, Panay N, Seitz C, Seymore S, Trower M, Zuurman L, Pawsey S. Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SW...
1 Simon JA, Anderson RA, Ballantyne E, Bolognese J, Caetano C, Joffe H, Kerr M, Panay N, Seitz C, Seymore S, Trower M, Zuurman L, Pawsey S. Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SW...
1 Simon JA, Anderson RA, Ballantyne E, Bolognese J, Caetano C, Joffe H, Kerr M, Panay N, Seitz C, Seymore S, Trower M, Zuurman L, Pawsey S. Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (...
1 Simon JA, Anderson RA, Ballantyne E, Bolognese J, Caetano C, Joffe H, Kerr M, Panay N, Seitz C, Seymore S, Trower M, Zuurman L, Pawsey S. Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SW...
Trial Registration: ClinicalTrials.gov Identifier: OASIS 1: NCT05042362, OASIS 2: NCT05099159 These 2 clinical trials evaluate the efficacy and safety of elinzanetant for the treatment of moderate to severe vasomotor symptoms associated with menopause.Pinkerton, JoAnn V....
Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1). Menopause. 2023;30(3):239-246. doi:10.1097/GME.0000000000002138PubMedGoogle ScholarCrossref 31. Trower M, Anderson RA, Bal...
OASIS 1和2是针对研究药物Elinzanetant开展的两项关键性临床研究。结果显示,研究达到了所有主要终点。与安慰剂组相比,治疗组中绝经后女性受试者的中度至重度血管舒缩症状(VMS)的频率和严重程度在统计学上有显著性降低。两项研究均显示,在所有关键次要终点的比较上,治疗组均优于安慰剂,其中第1周VMS的频率降低具有统...
拜耳将提交OASIS 1、2和3研究的数据给卫生监管当局,以支持elinzanetant用于治疗与绝经相关的中度至重度VMS的上市许可。 关于OASIS 1,2和3研究 OASIS 1 和 2(NCT05042362 和 NCT05099159)是双盲、随机、安慰剂对照的多中心研究,旨在研究 elinzanetant 每天口服一次治疗与绝经相关的中度至重度 VMS 女性在26周的疗效...
1 Simon JA, Anderson RA, Ballantyne E, Bolognese J, Caetano C, Joffe H, Kerr M, Panay N, Seitz C, Seymore S, Trower M, Zuurman L, Pawsey S. Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SW...
Bolognese J, Caetano C, Joffe H, Kerr M, Panay N, Seitz C, Seymore S, Trower M, Zuurman L, Pawsey S. Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1). Menopause. 2023 Mar 1;30(3)...